March 4, 2022
Life Sciences
  • Civica Rx, the nonprofit generic drug company created by a consortium of hospitals, announced that it plans to lower the cost of insulin by making it on its own. Civica plans to manufacture and distribute three different kinds of insulin at a cost of no more than $30 a vial and no more than $55 for a box of five pre-filled pens. Civica will co-develop and manufacture the drug products, complete the clinical trials, and file the necessary applications for FDA approval. The plan is to have the first insulin available to purchase by 2024. (Article here)